Annual Report to the Nation on the Status of Cancer, Featuring Cancer in Men and Women Age 20-49 Years.


Journal

Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089

Informations de publication

Date de publication:
01 12 2019
Historique:
received: 11 03 2019
revised: 09 05 2019
accepted: 20 05 2019
pubmed: 31 5 2019
medline: 12 6 2020
entrez: 31 5 2019
Statut: ppublish

Résumé

The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries provide annual updates on cancer occurrence and trends by cancer type, sex, race, ethnicity, and age in the United States. This year's report highlights the cancer burden among men and women age 20-49 years. Incidence data for the years 1999 to 2015 from the Centers for Disease Control and Prevention- and National Cancer Institute-funded population-based cancer registry programs compiled by the North American Association of Central Cancer Registries and death data for the years 1999 to 2016 from the National Vital Statistics System were used. Trends in age-standardized incidence and death rates, estimated by joinpoint, were expressed as average annual percent change. Overall cancer incidence rates (per 100 000) for all ages during 2011-2015 were 494.3 among male patients and 420.5 among female patients; during the same time period, incidence rates decreased 2.1% (95% confidence interval [CI] = -2.6% to -1.6%) per year in men and were stable in females. Overall cancer death rates (per 100 000) for all ages during 2012-2016 were 193.1 among male patients and 137.7 among female patients. During 2012-2016, overall cancer death rates for all ages decreased 1.8% (95% CI = -1.8% to -1.8%) per year in male patients and 1.4% (95% CI = -1.4% to -1.4%) per year in females. Important changes in trends were stabilization of thyroid cancer incidence rates in women and rapid declines in death rates for melanoma of the skin (both sexes). Among adults age 20-49 years, overall cancer incidence rates were substantially lower among men (115.3 per 100 000) than among women (203.3 per 100 000); cancers with the highest incidence rates (per 100 000) among men were colon and rectum (13.1), testis (10.7), and melanoma of the skin (9.8), and among women were breast (73.2), thyroid (28.4), and melanoma of the skin (14.1). During 2011 to 2015, the incidence of all invasive cancers combined among adults age 20-49 years decreased -0.7% (95% CI = -1.0% to -0.4%) among men and increased among women (1.3%, 95% CI = 0.7% to 1.9%). The death rate for (per 100 000) adults age 20-49 years for all cancer sites combined during 2012 to 2016 was 22.8 among men and 27.1 among women; during the same time period, death rates decreased 2.3% (95% CI = -2.4% to -2.2%) per year among men and 1.7% (95% CI = -1.8% to -1.6%) per year among women. Among people of all ages and ages 20-49 years, favorable as well as unfavorable trends in site-specific cancer incidence were observed, whereas trends in death rates were generally favorable. Characterizing the cancer burden may inform research and cancer-control efforts.

Sections du résumé

BACKGROUND
The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries provide annual updates on cancer occurrence and trends by cancer type, sex, race, ethnicity, and age in the United States. This year's report highlights the cancer burden among men and women age 20-49 years.
METHODS
Incidence data for the years 1999 to 2015 from the Centers for Disease Control and Prevention- and National Cancer Institute-funded population-based cancer registry programs compiled by the North American Association of Central Cancer Registries and death data for the years 1999 to 2016 from the National Vital Statistics System were used. Trends in age-standardized incidence and death rates, estimated by joinpoint, were expressed as average annual percent change.
RESULTS
Overall cancer incidence rates (per 100 000) for all ages during 2011-2015 were 494.3 among male patients and 420.5 among female patients; during the same time period, incidence rates decreased 2.1% (95% confidence interval [CI] = -2.6% to -1.6%) per year in men and were stable in females. Overall cancer death rates (per 100 000) for all ages during 2012-2016 were 193.1 among male patients and 137.7 among female patients. During 2012-2016, overall cancer death rates for all ages decreased 1.8% (95% CI = -1.8% to -1.8%) per year in male patients and 1.4% (95% CI = -1.4% to -1.4%) per year in females. Important changes in trends were stabilization of thyroid cancer incidence rates in women and rapid declines in death rates for melanoma of the skin (both sexes). Among adults age 20-49 years, overall cancer incidence rates were substantially lower among men (115.3 per 100 000) than among women (203.3 per 100 000); cancers with the highest incidence rates (per 100 000) among men were colon and rectum (13.1), testis (10.7), and melanoma of the skin (9.8), and among women were breast (73.2), thyroid (28.4), and melanoma of the skin (14.1). During 2011 to 2015, the incidence of all invasive cancers combined among adults age 20-49 years decreased -0.7% (95% CI = -1.0% to -0.4%) among men and increased among women (1.3%, 95% CI = 0.7% to 1.9%). The death rate for (per 100 000) adults age 20-49 years for all cancer sites combined during 2012 to 2016 was 22.8 among men and 27.1 among women; during the same time period, death rates decreased 2.3% (95% CI = -2.4% to -2.2%) per year among men and 1.7% (95% CI = -1.8% to -1.6%) per year among women.
CONCLUSIONS
Among people of all ages and ages 20-49 years, favorable as well as unfavorable trends in site-specific cancer incidence were observed, whereas trends in death rates were generally favorable. Characterizing the cancer burden may inform research and cancer-control efforts.

Identifiants

pubmed: 31145458
pii: 5498721
doi: 10.1093/jnci/djz106
pmc: PMC6910179
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1279-1297

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press.

Références

J Registry Manag. 2018 Spring;45(1):33-36
pubmed: 30183695
Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):619-626
pubmed: 29593010
Cancer. 1998 Mar 15;82(6):1197-207
pubmed: 9506368
MMWR Morb Mortal Wkly Rep. 2016 Nov 11;65(44):1212-1218
pubmed: 27832048
J Registry Manag. 2014 Summer;41(2):51-6
pubmed: 25153009
Handb Clin Neurol. 2014;124:361-71
pubmed: 25248599
Am J Surg Pathol. 2016 Dec;40(12):e94-e102
pubmed: 27740970
J Natl Cancer Inst. 2008 Dec 3;100(23):1672-94
pubmed: 19033571
Endocr Pract. 2015 Jun;21(6):686-96
pubmed: 26135963
Hematol Oncol Clin North Am. 2012 Aug;26(4):855-79
pubmed: 22794287
Breast Cancer Res Treat. 2019 Feb;173(3):743-747
pubmed: 30426307
JAMA. 2017 Aug 8;318(6):572-574
pubmed: 28787497
J Natl Cancer Inst. 2017 Aug 1;109(8):
pubmed: 28376186
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Arch Pathol Lab Med. 2015 May;139(5):587-93
pubmed: 25275812
Cancer. 2007 Nov 15;110(10):2119-52
pubmed: 17939129
Womens Health (Lond). 2015 Jan;11(1):65-77
pubmed: 25581056
Breast Cancer Res Treat. 2013 Feb;137(3):869-82
pubmed: 23274845
PLoS One. 2013 Dec 27;8(12):e83261
pubmed: 24386167
Medicine (Baltimore). 2017 Dec;96(50):e9125
pubmed: 29390313
Lancet Oncol. 2017 Dec;18(12):1579-1589
pubmed: 29111259
Occup Environ Med. 2018 Aug;75(8):593-603
pubmed: 29769352
CA Cancer J Clin. 2008 Jan-Feb;58(1):9-31
pubmed: 18096863
J Environ Public Health. 2017;2017:2819372
pubmed: 28408935
JAMA. 2013 Feb 27;309(8):800-5
pubmed: 23443443
Andrology. 2015 Jan;3(1):13-8
pubmed: 25331158
Support Care Cancer. 2018 Jul;26(7):2209-2215
pubmed: 29387996
Cancer. 2010 Feb 1;116(3):544-73
pubmed: 19998273
Cancer. 2016 May 1;122(9):1312-37
pubmed: 26959385
JAMA. 2017 Feb 7;317(5):516-524
pubmed: 28170483
J Natl Cancer Inst. 2015 Mar 30;107(6):djv048
pubmed: 25825511
Breast Cancer Res. 2016 Aug 04;18(1):79
pubmed: 27492244
Andrology. 2015 Jan;3(1):19-26
pubmed: 25538016
Neuroendocrinology. 2019;109(1):20-27
pubmed: 30731464
J Natl Cancer Inst. 2008 Dec 17;100(24):1763-70
pubmed: 19066273
Cancer. 2014 May 1;120(9):1290-314
pubmed: 24343171
J Adolesc Young Adult Oncol. 2017 Jun;6(2):327-332
pubmed: 28103126
CA Cancer J Clin. 2018 Jul;68(4):250-281
pubmed: 29846947
Nat Rev Clin Oncol. 2017 Aug;14(8):463-482
pubmed: 28374786
J Natl Cancer Inst. 2013 Feb 6;105(3):175-201
pubmed: 23297039
Stat Med. 2000 Feb 15;19(3):335-51
pubmed: 10649300
Biomol Ther (Seoul). 2018 Jul 1;26(4):335-342
pubmed: 29949843
Cancer. 2006 Apr 1;106(7):1425-30
pubmed: 16544312
Breast Cancer (Dove Med Press). 2015 Dec 21;8:1-12
pubmed: 26730210
J Natl Cancer Inst. 1999 Apr 21;91(8):675-90
pubmed: 10218505
Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1174-82
pubmed: 19293308
J Registry Manag. 2014 Summer;41(2):57-64
pubmed: 25153010
Cancer. 2004 Jul 1;101(1):3-27
pubmed: 15221985
J Natl Cancer Inst Monogr. 2014 Nov;2014(49):198-209
pubmed: 25417233
Cancer. 2006 Oct 15;107(8):1711-42
pubmed: 16958083
BMJ. 2014 Apr 28;348:g2756
pubmed: 24778341
Breast Cancer Res Treat. 2013 Nov;142(1):165-75
pubmed: 24136668
Semin Cancer Biol. 2019 Apr;55:16-27
pubmed: 29857039
Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1121-7
pubmed: 15247122
J Natl Cancer Inst. 2001 Jun 6;93(11):824-42
pubmed: 11390532
J Natl Compr Canc Netw. 2015 Apr;13(4):376-8
pubmed: 25870373
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
MMWR Morb Mortal Wkly Rep. 2018 Aug 24;67(33):909-917
pubmed: 30138305
Int J Clin Pract. 2010 Mar;64(4):475-87
pubmed: 20456194
Cancer. 2002 May 15;94(10):2766-92
pubmed: 12173348
World Neurosurg. 2018 Mar;111:e149-e159
pubmed: 29248774
Adv Urol. 2018 Feb 18;2018:8671832
pubmed: 29670654
Cancer. 2012 May 1;118(9):2338-66
pubmed: 22460733
Melanoma Res. 2018 Feb;28(1):56-60
pubmed: 29023264
J Neurooncol. 2010 Sep;99(3):307-14
pubmed: 20821343
J Natl Cancer Inst. 2003 Sep 3;95(17):1276-99
pubmed: 12953083
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28376154
N Engl J Med. 2018 Sep 06;379(10):990-991
pubmed: 30184458
J Natl Cancer Inst. 2005 Oct 5;97(19):1407-27
pubmed: 16204691
Laryngoscope. 2017 Oct;127(10):2437-2441
pubmed: 28092116
J Community Health. 2015 Jun;40(3):414-8
pubmed: 25301588
Am J Prev Med. 2016 Nov;51(5):673-681
pubmed: 27745677
Stat Med. 2009 Dec 20;28(29):3670-82
pubmed: 19856324
J Investig Med. 2017 Feb;65(2):311-315
pubmed: 27864324
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
Breast Cancer Res Treat. 2018 Jun;169(3):595-606
pubmed: 29445940
Cancer. 2018 Jul 1;124(13):2801-2814
pubmed: 29786851
Cancer. 2016 Apr 1;122(7):1000-8
pubmed: 26848808
J Natl Cancer Inst. 2011 May 4;103(9):714-36
pubmed: 21454908
JAMA. 2015 Nov 17;314(19):2054-61
pubmed: 26575061
Cancer. 2000 May 15;88(10):2398-424
pubmed: 10820364
Cancer Epidemiol Biomarkers Prev. 2011 Aug;20(8):1629-37
pubmed: 21750167

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH